In a report released today, Serge Belanger from Needham maintained a Hold rating on Clearside Biomedical (CLSD – Research Report). The company's shares closed last Tuesday at $1.59, close to its 52-week low of $1.26. According to TipRanks.com, Belanger is a 3-star analyst with an average return of 1.6% and a 42.9% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and KalVista Pharmaceuticals. Currently, the analyst consensus on Clearside Biomedical is a Strong Buy with an average price target of $9.67.
https://www.tipranks.com/news/blurbs/clearside-biomedical-clsd-receives-a-hold-from-needham-4?utm_source=advfn.com&utm_medium=referral